- Alcon (ALC, Financial) to enhance its retinal treatment portfolio with the acquisition of LumiThera.
- Analysts offer an average one-year price target of $106.53, reflecting potential growth.
- Current analyst consensus rates Alcon as "Outperform" with a recommendation score of 1.7.
Alcon (ALC) is set to expand its offerings in the field of eye care with a strategic acquisition of LumiThera, a company known for its innovative photobiomodulation device for early and intermediate stages of dry age-related macular degeneration (AMD). This acquisition aligns with Alcon's vision to enhance its spectrum of office-based treatments for retinal disorders across approved regions, promising a broader reach and improved treatment outcomes.
Wall Street Analysts Forecast
As per the projections of 15 analysts over the next year, Alcon Inc (ALC, Financial) carries an average price target of $106.53. The forecasts range with a high of $123.00 and a low of $85.00, suggesting a potential upside of 21.36% from the current price of $87.78. Investors can explore further details on these estimates on the Alcon Inc (ALC) Forecast page.
According to insights from 18 brokerage firms, Alcon Inc (ALC, Financial) holds an average brokerage recommendation of 1.7, conveying an "Outperform" rating. This recommendation is based on a scale where 1 indicates a Strong Buy and 5 indicates a Sell. This score reflects a positive outlook among analysts, suggesting that Alcon is poised for growth in the foreseeable future.
Examining GuruFocus estimates, the one-year GF Value for Alcon Inc (ALC, Financial) stands at $92.86, implying a potential upside of 5.79% from its current trading price of $87.78. The GF Value is a metric developed by GuruFocus to estimate the fair value of a stock, calculated considering historical trading multiples, previous business growth, and projections of future performance. Detailed analysis and data are available on the Alcon Inc (ALC) Summary page.
